公开(公告)号：US20190310258A1

公开(公告)日：2019-10-10

申请号：US16345539

申请日：2017-10-26

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH ,  OSAKA UNIVERSITY

Inventor： Koji Ueda ,  Naomi Ohnishi ,  Norio Nonomura ,  Motohide Uemura ,  Kazutoshi Fujita ,  Kazutake Tsujikawa ,  Kentarou Jingushi

IPC: G01N33/574 ,  C12Q1/6886

Abstract: Provided is a method wherein an affected tissue and a normal tissue obtained from the vicinity of the affected tissue are left at rest in a culture medium, and a disease-specific biomarker is searched for in an exudate therefrom. A biomarker specific to renal cell carcinoma has been found by this method.

公开(公告)号：US09212169B2

公开(公告)日：2015-12-15

申请号：US14382048

申请日：2013-03-01

Applicant: HYOGO COLLEGE OF MEDICINE ,  KAGOSHIMA UNIVERSITY ,  OSAKA UNIVERSITY

Inventor： Kazutake Tsujikawa ,  Akito Tanaka ,  Shunji Aoki ,  Hiroaki Mizuno ,  Miyuki Tokoro ,  Tatsuhiko Furukawa

IPC: C07D403/04

CPC classification number: C07D403/04

Abstract: The present invention aims to provide a compound capable of inhibiting PCA-1 that can be a target for a novel treatment method of various diseases, and pharmaceutical use of the compound. A compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof.

Abstract translation: 本发明的目的在于提供能够抑制作为各种疾病的新型治疗方法的靶标的PCA-1的化合物和该化合物的药物用途。 由式（I）表示的化合物或其药学上可接受的盐，其中每个符号如说明书中所定义。

公开(公告)号：US20150011600A1

公开(公告)日：2015-01-08

申请号：US14382048

申请日：2013-03-01

Applicant: HYOGO COLLEGE OF MEDICINE ,  KAGOSHIMA UNIVERSITY ,  OSAKA UNIVERSITY

Inventor： Kazutake Tsujikawa ,  Akito Tanaka ,  Shunji Aoki ,  Hiroaki Mizuno ,  Miyuki Tokoro ,  Tatsuhiko Furukawa

IPC: C07D403/04

CPC classification number: C07D403/04

Abstract: The present invention aims to provide a compound capable of inhibiting PCA-1 that can be a target for a novel treatment method of various diseases, and pharmaceutical use of the compound. A compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof.

Abstract translation: 本发明的目的在于提供能够抑制作为各种疾病的新型治疗方法的靶标的PCA-1的化合物和该化合物的药物用途。 由式（I）表示的化合物或其药学上可接受的盐，其中每个符号如说明书中所定义。